Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seelos Therapeutics Inc (SEEL)

Seelos Therapeutics Inc (SEEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,299
  • Shares Outstanding, K 44,950
  • Annual Sales, $ 380 K
  • Annual Income, $ -51,260 K
  • 60-Month Beta 1.94
  • Price/Sales 127.06
  • Price/Cash Flow N/A
  • Price/Book 6.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9600 +7.29%
on 07/29/20
1.3000 -20.77%
on 07/30/20
+0.0200 (+1.98%)
since 07/14/20
3-Month
0.7200 +43.06%
on 05/15/20
1.7000 -39.41%
on 06/23/20
+0.2900 (+39.19%)
since 05/14/20
52-Week
0.4195 +145.53%
on 04/02/20
1.9800 -47.98%
on 08/22/19
-0.5600 (-35.22%)
since 08/14/19

Most Recent Stories

More News
Seelos Therapeutics Receives FDA May Proceed Notice to Initiate a Phase IIb/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,

SEEL : 1.0300 (-2.83%)
Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,...

SEEL : 1.0300 (-2.83%)
Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced...

SEEL : 1.0300 (-2.83%)
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease

, /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,...

SEEL : 1.0300 (-2.83%)
Thinking about buying stock in Trevena, Translate Bio, Workhorse Group, Dynavax Technologies, or Seelos Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRVN, TBIO, WKHS, DVAX, and SEEL.

SEEL : 1.0300 (-2.83%)
Psychedelic-derived Therapies are Just What the Doctor Ordered to Address a Historic Mental Illness Epidemic

, /PRNewswire/ -- While the global death toll caused by the pandemic is well-publicized, a lesser-known side effect of the ongoing pandemic is the rise in mental illness that it has generated. Due to...

SEEL : 1.0300 (-2.83%)
SHRM.CN : 0.890 (+3.49%)
SHRMF : 0.4400 (-6.38%)
NUMI.VN : 0.260 (unch)
LKYSD : 0.3330 (+17.54%)
JNJ : 148.24 (+0.16%)
MMEDF : 0.3878 (+1.57%)
Psychedelic Products Gain Traction for Medicinal Purposes

, /PRNewswire/ -- Over the course of the past decade, several universities and research institutes have published breakthrough findings from studies conducted on the usefulness and applications of psychedelic...

SEEL : 1.0300 (-2.83%)
DYAI : 7.66 (-13.84%)
NLBIF : 0.6150 (-6.82%)
NLB.CN : 1.000 (+12.36%)
MMEDF : 0.3878 (+1.57%)
SHRMF : 0.4400 (-6.38%)
SHRM.CN : 0.890 (+3.49%)
Researchers Cast Gaze Towards Psychedelics in Search of Novel Therapies

The current pandemic has caught people and the healthcare systems off guard; the measures taken, such mandatory quarantines and social distancing, do have side effects. According to Mailman School of Public...

PSYC : 0.0105 (+5.00%)
MMEDF : 0.3878 (+1.57%)
SEEL : 1.0300 (-2.83%)
CBWTF : 0.1700 (-0.76%)
XLY.VN : 0.225 (-2.17%)
CWBHF : 3.7300 (+6.88%)
CWEB.TO : 4.96 (+7.36%)
Mental Health Comes Face to Face With Psychedelics

Over the course of the past decade, several universities and research institutes have published breakthrough findings from studies conducted on the usefulness and applications of psilocybin. The substance...

JAZZ : 124.26 (+0.93%)
PSYC : 0.0105 (+5.00%)
SEEL : 1.0300 (-2.83%)
DYAI : 7.66 (-13.84%)
MMEDF : 0.3878 (+1.57%)
SHRMF : 0.4400 (-6.38%)
SHRM.CN : 0.890 (+3.49%)
Innovative Approaches to Healthcare Lead to the Psychedelic Biotech Market's Inception

The fast pace of technological change in the biotechnology industry and the shifting market demands require continuous innovation. This, in turn, puts pressure on companies to invest in Research and Development....

SHRMF : 0.4400 (-6.38%)
SHRM.CN : 0.890 (+3.49%)
SEEL : 1.0300 (-2.83%)
JNJ : 148.24 (+0.16%)
OSUR : 13.18 (-1.93%)
VYGR : 11.27 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade SEEL with:

Business Summary

Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which...

See More

Key Turning Points

2nd Resistance Point 1.0633
1st Resistance Point 1.0467
Last Price 1.0300
1st Support Level 1.0067
2nd Support Level 0.9833

See More

52-Week High 1.9800
Fibonacci 61.8% 1.3839
Fibonacci 50% 1.1997
Last Price 1.0300
Fibonacci 38.2% 1.0156
52-Week Low 0.4195

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar